Electronic submissions to the FDA will soon no longer be optional – this new guidance requires e-submission for many types of submissions. The FDA final guidance document, Providing Regulatory Submissions for Medical Devices in Electronic Format – Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act, was issued on July 15, 2020.
Under this guidance, electronic submission will be required for:
- De Novo
Additionally, all follow-on submissions to these listed submissions, like supplements and reports, must also be in electronic format. Although the FDA has not yet disclosed how a potential waiver process will work, they have listed some exemptions to the e-submission requirement. Expanded access compassionate use requests, emergency use reports, and adverse event reports will not be required to follow the electronic submission guidance.
The individual draft guidance documents for the various types of submissions will be released sequentially. They will address the electronic format, subject matter, and scope for each type of submission. FDA said that, “Once an individual guidance is finalized and published on FDA’s Web site, and the timetable for implementation described in that guidance has passed, the guidance will be considered to have binding effect.” This means that the start date for the required electronic format is still unknown – and it will likely be different for each specific submission, as the individual submission guidances will be released sequentially.
Be sure to check our website regularly to be notified when the individual e-submission guidances are released.
See all of our FDA-related posts here: https://www.softwarecpr.com/tag/fda/